MET and cancer: Tivantinib (ARQ 197; ArQule, Burlington, MA; Daichi-Sankyo, Tokyo, Japan) is an orally available selective small molecule that inhibits MET receptor tyrosine kinase with a novel ATP independent binding (allosteric inhibitor) mechanism, leading to inhibition of cell proliferation and induction of apoptosis in MET-expressing cancer cells.